Vera Therapeutics, Inc. — Form 8-K Summary
Reporting period/event date: Current report filed July 14, 2021, covering executive leadership changes effective July 12 and July 14, 2021. Vera Therapeutics is a Delaware biotechnology company whose Class A common stock trades on Nasdaq under “VERA.”
Key Financial Metrics and Liquidity
The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other financial statement metrics. It is limited primarily to executive appointments, compensation arrangements, and related disclosures.
Material Changes Versus the Prior Period
- Sean P. Grant was appointed Chief Financial Officer and principal financial officer, effective July 12, 2021.
- Jonathan Wolter resigned as Chief Financial Officer and principal financial officer, effective July 14, 2021.
- The company stated that Mr. Wolter’s resignation was not related to any disagreement concerning the company’s operations, policies, or practices.
Compensation and Employment Terms
- Mr. Grant will receive an annual base salary of $400,000 and may earn an annual performance bonus of up to 40% of base salary, prorated for 2021.
- He will receive a $60,000 commencement advance, subject to the employment-continuation conditions described in the offer letter.
- Subject to board approval, he will receive an option to purchase 180,000 shares of Class A common stock at an exercise price equal to the fair market value on the grant date.
- The option is scheduled to vest over four years, with 25% vesting after one year and the remainder vesting in equal monthly installments over the following 36 months.
- Upon specified qualifying terminations, Mr. Grant is eligible for nine months of salary continuation and health-care coverage. Certain qualifying terminations around a change in control would provide 12 months of severance and benefits, target-bonus payment, and accelerated vesting of unvested equity.
Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. Key items for investors include the potential future cost of salary, bonus, equity compensation, severance, health-care benefits, and change-in-control protections under the new CFO’s employment agreement. The detailed terms are contained in Exhibit 10.1, the May 30, 2021 offer letter.
Investor Verification Checklist
- Confirm the effective dates and scope of the CFO transition in subsequent filings.
- Review Exhibit 10.1 for the complete compensation, termination, and change-in-control provisions.
- Assess the potential dilution and expense associated with the proposed 180,000-share stock option after board approval and grant.
- Review subsequent periodic reports for financial results, cash position, liquidity, and any effects from the executive transition.